AI-powered, integrated digital health company MedPal AI plc (AIM: MPAL) (FRA: Z1N) declared on Wednesday that it has launched its MedPal Health Operating System, a vertically integrated digital health platform designed to deliver personalised, data-driven healthcare at scale across the UK.
The platform combines wearable data aggregation, AI-led triage, clinician-supported prescribing and automated robotic dispensing into a closed-loop system, which the company believes is the first of its kind in the UK. The MedPal AI app integrates data from more than 100 wearable devices and health applications, creating real-time patient health profiles to support continuous monitoring and intervention.
Using clinician-trained AI, the system generates personalised health insights and flags potential treatments, which are reviewed by clinicians before prescriptions are issued. Fulfilment is handled through BD Rowa VMAX robotic dispensing infrastructure, capable of processing over 200 items per hour with 99.99% accuracy. Patient outcomes are then fed back into the data loop, enabling ongoing optimisation of care.
The company said the platform represents a shift from traditional, episodic healthcare delivery to a continuous, proactive model, supported by additional inputs including at-home blood testing to enhance clinical data. MedPal AI expects the Health OS to underpin long-term growth through consumer adoption, B2B licensing and its partnership with Epassi UK Limited, which provides access to more than 11 million employees. The company also highlighted the compounding value of its proprietary data ecosystem as a key competitive advantage.
MedPal AI operates a 24/7 automated pharmacy distribution centre via its subsidiary MedPal Limited, delivering NHS and private prescriptions nationwide through AI-enabled fulfilment systems.
Shield Therapeutics announces Phase II trial initiation of ACCRUFeR in Japan for PAH
Johnson & Johnson secures EU approval for ETHICON 4000 surgical stapler
Implantica publishes large-scale RefluxStop study showing strong long-term safety outcomes
Orthocell gains approval for Remplir across US defence and veterans hospital networks
QT Imaging Debuts QT Imaging-Olea Viewer for integrated multimodality breast imaging
CS Analytical appoints director of Scientific Affairs
MedPal AI launches integrated health OS platform to drive scalable digital healthcare
QT Imaging launches next-generation breast imaging reconstruction software
Tempus and Medtronic report positive ALERT trial results for AI-driven cardiac care
US FDA approves i-Lumen Scientific's i-SIGHT2 clinical study for dry AMD
Edwards Lifesciences reports positive two-year data for EVOQUE valve system
Clarity Pharmaceuticals signs copper-64 manufacturing agreement with Theragenics